*Review* **Plasminogen Activators in Neurovascular and Neurodegenerative Disorders**

**Manuel Yepes 1,2,3,\*, Yena Woo 2 and Cynthia Martin-Jimenez 2**

cynthia.alexandra.martin-jimemez@emory.edu (C.M.-J.) 3 DepartmentofNeurology,VeteransAffairsMedicalCenter,Decatur,GA30329,USA

 **\*** Correspondence: myepes@emory.edu

**Abstract:** The neurovascular unit (NVU) is a dynamic structure assembled by endothelial cells surrounded by a basement membrane, pericytes, astrocytes, microglia and neurons. A carefully coordinated interplay between these cellular and non-cellular components is required to maintain normal neuronal function, and in line with these observations, a growing body of evidence has linked NVU dysfunction to neurodegeneration. Plasminogen activators catalyze the conversion of the zymogen plasminogen into the two-chain protease plasmin, which in turn triggers a plethora of physiological events including wound healing, angiogenesis, cell migration and inflammation. The last four decades of research have revealed that the two mammalian plasminogen activators, tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), are pivotal regulators of NVU function during physiological and pathological conditions. Here, we will review the most relevant data on their expression and function in the NVU and their role in neurovascular and neurodegenerative disorders.

**Keywords:** tissue-type plasminogen activator (tPA); urokinase-type plasminogen activator (uPA); neurodegeneration
